We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Swaminathan Iyer MD

Swaminathan P Iyer MD

Dr. Swami P. Iyer, is a Professor of Medicine in the Department of Lymphoma/Myeloma at University of Texas, MD Anderson. He is a physician scientist with extensive expertise in clinical studies particularly in Hematological Malignancies such as leukemia and lymphoma, in addition to laboratory interests in developing small molecules, aptamers and drug delivery technologies such as nanoparticles into the clinic. He has led many trials including first-in-man studies, exploration of different doses and schedules of administration and investigational agent combinations, and the examination of biomarkers for patient selection. Some of these agents include inhibitors of Aurora Kinases, Hsp90, Hedgehog pathways and MDM2 and monoclonal Antibodies such as GA101, Ofatumumab, BHQ880, and Anti-KIR in hematological malignancies. He was part of pivotal studies that led to the FDA approval of the new anti-CD20 monoclonal antibody Ofatumumab or Arzerra in Chronic Lymphocytic Leukemia and the Histone Deacetylase inhibitor Romidepsin or Istodax in Peripheral T cell Lymphomas. He leads the T cell lymphoma program at MD Anderson. His laboratory interests are in developing aptamers against targets in hematological malignancies and has a patent for specific oligonucleotides against programmed cell death receptor PD1. These anti-PD-1 DNA aptamers demonstrable ability to block PD- 1: PD-L1 interaction, prime the innate immune system and significantly reduce the growth of leukemic tumor cells in humanized NSG mice.